IP Library Granted Patent US 9,572,936
Granted Patent B2
US 9,572,936 · App. 14/063,790 · Granted Feb 21, 2017

Integrated insulin delivery system with continuous glucose sensor

Inventors: John Michael Dobbles (San Clemente, CA); Apurv Ullas Kamath (San Diego, CA); Aarthi Mahalingam (San Diego, CA); James H. Brauker (Addison, MI)
Assignee: DexCom, Inc.
A61M5/1723A61B5/14532A61B5/14546A61M5/14244G06F19/3468A61B5/0031A61M5/003A61M5/178A61M5/30A61M11/00A61M15/00A61M2005/14296A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,572,936
App. No.
14/063,790
Granted
Feb 21, 2017
Kind
B2
Abstract

Systems and methods for integrating a continuous glucose sensor 12 , including a receiver 14 , a medicament delivery device 16 , a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.

Claims (27)

1. An integrated system for monitoring a glucose concentration in a host and for delivering insulin to the host, the system comprising:

a continuous glucose sensor, wherein the continuous glucose sensor is configured to substantially continuously measure a glucose concentration in a host, and to provide sensor data associated with the glucose concentration of the host;

an electronics module comprising a bolus controller module configured to iteratively determine an insulin therapy instruction in response to an evaluation of a relationship of internally derived data and an engageable bolus constraint, wherein a relationship of internally derived data to the bolus constraint is evaluated in response to engagement of the bolus constraint, and wherein the bolus constraint comprises a maximum total insulin dose that can be delivered within a predefined time period in response to engagement of the bolus constraint; and

an insulin delivery device configured to deliver insulin to the host, wherein the insulin delivery device is at least one of physically connected to a receiver and/or operably connected to a receiver, and wherein the insulin delivery device is configured to receive the insulin therapy instruction from the controller module.

2. The integrated system of claim 1 , wherein the insulin therapy instruction is determined solely on internally derived data and the bolus constraint.

3. The integrated system of claim 1 , wherein the system further comprises at least one of a selectable button configured to allow a user to engage the engageable bolus constraint, a scroll wheel configured to allow a user to engage the engageable bolus constraint, or a menu selection configured to allow a user to engage the engageable bolus constraint.

4. The integrated system of claim 1 , wherein the insulin therapy instruction comprises an instruction to deliver a portion of the maximum total insulin dose.

5. The integrated system of claim 1 , wherein the insulin delivery device is configured to deliver insulin automatically in response to receiving the insulin therapy instruction.

6. The integrated system of claim 1 , wherein the bolus constraint is programmable by at least one of the host and a caretaker of the host.

7. The integrated system of claim 1 , wherein the bolus constraint is programmable by at least one of the bolus controller module and a manufacturer of the integrated system.

8. The integrated system of claim 1 , wherein the insulin delivery device is configured to provide delivery device data associated with insulin delivery.

9. The integrated system of claim 8 , wherein the internally derived data comprises at least one of sensor data, processed sensor data, delivery device data or processed delivery device data.

10. The integrated system of claim 9 , wherein the internally derived data further comprises at least one of a glucose concentration, a glucose concentration range, a change in glucose concentration, a glucose concentration rate of change, an acceleration of a glucose concentration rate of change, a host insulin sensitivity, a change in host insulin sensitivity, a host metabolic response to insulin therapy, an amount of insulin delivered, a time of insulin delivery, an insulin on board, or a time.

11. An method for monitoring a glucose concentration in a host and for delivering insulin to the host, the method comprising:

providing sensor data associated with the glucose concentration of the host;

evaluating a relationship of internally derived data and an engageable bolus constraint;

determining an insulin therapy instruction, using a bolus controller module of a processor, in response to the evaluation, wherein a relationship of internally derived data to the bolus constraint is evaluated in response to engagement of the bolus constraint, and wherein the bolus constraint comprises a maximum total insulin dose that can be delivered within a predefined time period in response to engagement of the bolus constraint; and

delivering insulin to the host based on the insulin therapy instruction from the bolus controller module.

12. The method of claim 11 , wherein the determining is based solely on internally derived data and the bolus constraint.

13. The method of claim 11 , wherein the method further comprises engaging the engageable bolus constraint.

14. The method of claim 11 , wherein the insulin therapy instruction comprises an instruction to deliver a portion of the maximum total insulin dose.

15. The method of claim 11 , wherein the delivering insulin is automatically performed in response to receiving the insulin therapy instruction.

16. The method of claim 11 , wherein the bolus constraint is programmable by at least one of the host and a caretaker of the host.

17. The method of claim 11 , wherein the bolus constraint is programmable by at least one of the bolus controller module and a manufacturer of the method.

18. The method of claim 11 , further comprising providing delivery device data associated with insulin delivery.

19. The method of claim 18 , wherein the internally derived data comprises at least one of sensor data, processed sensor data, delivery device data or processed delivery device data.

20. The method of claim 19 , wherein the internally derived data comprises at least one of a glucose concentration, a glucose concentration range, a change in glucose concentration, a glucose concentration rate of change, an acceleration of a glucose concentration rate of change, a host insulin sensitivity, a change in host insulin sensitivity, a host metabolic response to insulin therapy, an amount of insulin delivered, a time of insulin delivery, an insulin on board, or a time.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2014
From: DOBBLES, MIKE; KAMATH, APURV ULLAS; MAHALINGAM, AARTHI; BRAUKER, JAMES H.
To: DEXCOM, INC.
Reel/Frame 031986/0251 →
Continuity (2)
Continuation 13885604
Related Publication 20140052092A1 · Feb 20, 2014